TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07695142: A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 Tablets in Patients With Advanced Solid Tumors

Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 275 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07695142 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07695142 Rescue Dossier →